Sree Rayalaseema Hi-Strength Hypo Limited
Valuation (94/100) does the heavy lifting; financial trend (19/100) is the drag.
Buy zoneOur blended model reads Sree Rayalaseema Hi-Strength Hypo Limited as a Hold at 52/100. At ₹484.4 it trades below our blended DCF and relative-multiples fair value of ₹807.15, about 67% upside to that estimate — we read it as undervalued by 67%. On 9.3x trailing earnings it sits cheaper than the Basic Materials median of about 22.2x. The price is about 25% below its 52-week high of ₹646.74 and 26% above the low of ₹384. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 7 of 13 investability checks, with durability 54, valuation 87 and momentum 21 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹645.72.
1-year price
EOD · 2026-07-3152-week range
-25.10% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold52Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.4%
- Pass: Low debt (D/E < 0.5): 0.01x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 2%
- Fail: Earnings growing: -17%
- Pass: Net margin ≥ 10%: 13.5%
- Pass: Current ratio > 1.5: 10.55
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.9
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Shareholding
- Promoter68.6%
- Institutions0.0%
- Public & other31.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 5.9.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~67% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Sree Rayalaseema Hi-Strength Hypo Limited
Sree Rayalaseema Hi-Strength Hypo Limited manufactures and sells industrial chemicals in India across three business segments: chemical manufacturing, power generation, and coal trading. The company produces acids including sulphuric, chlorosulphonic, hydrochloric, and monochloro acetic; chlorine-based compounds such as purichlor, chloramine, and sodium dichloroisocyanurate; and specialty chemicals including aluminum sulphate, sodium methoxide, hydrogen gas, and water treatment products.
Sree Rayalaseema Hi-Strength Hypo Limited — frequently asked questions
Is Sree Rayalaseema Hi-Strength Hypo Limited a buy, hold or sell?
StocksWizard currently rates Sree Rayalaseema Hi-Strength Hypo Limited (SRHHYPOLTD) a Hold, based on a blended score of 52/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Sree Rayalaseema Hi-Strength Hypo Limited's fair value?
Our blended DCF and relative-valuation model estimates Sree Rayalaseema Hi-Strength Hypo Limited's fair value at about ₹807.15, versus a current price of ₹484.4 — roughly 67% upside. On that basis the stock looks undervalued by 67%.
Is Sree Rayalaseema Hi-Strength Hypo Limited financially healthy?
Sree Rayalaseema Hi-Strength Hypo Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Sree Rayalaseema Hi-Strength Hypo Limited's share price performed?
Sree Rayalaseema Hi-Strength Hypo Limited is down 6% over three months, and last traded at ₹484.4. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.